Villalpando-Gómez Y, Rocha-Muñoz AD, Rodríguez-Hernández DM, Tejeda-Andrade CF, Gámez-Nava JI, González-López L

Language: Spanish
References: 10
Page: 38-43
PDF size: 302.04 Kb.

ABSTRACT

Introduction: Progressive systemic sclerosis (PSS) is an autoimmune disease characterized by extensive fibrosis of the skin and internal organs were the interstitial lung disease (ILD) is highly prevalent. One of the clinical variables predictive of mortality is the impairment of the 6 minute walk test (6MWT). So far little information exists in Mexico to the variables associated with impairment in the 6MWT. Objective: To evaluate the factors that correlate with an impairment in the 6MWT in patients with ILD secondary to PSS. Material and methods: Cross-sectional study. Fifteen women with ILD secondary to PSS. Was performed a correlation between the 6MWT and several variables. Analysis: Spearman test for quantitative variables correlate with the impairment in the 6MWT. Results: The variables that correlated with the deterioration in the 6MWT were functional impairment (rho = 0.6, p = 0.01), impaired well-being (rho = -0.6, p = 0.05), greater fatigue (rho =-0.7, p = 0.01) and dyspnea pre (rho =- 0.79, p ‹0.001) and post exercise (rho =-0.76, p = 0.01). Conclusions: The 6MWT is a widely used tool for assessing the impact of ILD in patients with PSS but can be affected by many factors and it is of great importance to understand other variables that are associated with pulmonary deterioration

REFERENCES

1. Shaun R. Kelley’s Textbook of Rheumatology. 6th edition, Editorial 2001; 27-38: 1211-1235.

2. Steen V, Medsger T. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444.

3. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-1296.

4. Gauldie J. Inflammatory mechanisms are a minor component of pathogenesis of idiopathic pulmonary fibrosis. Am J Resp Crit Med 2002; 165: 1205-1208.

5. Xaubet A, Anochea R, Blanquer R et al. Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas. Arch Bronconeumol 2003; 39: 580-600.

6. Valentini G, Della RA, Bombardieri S et al. European multicentre study criteria of systemic sclerosis. Identification of disease activity variable and development of preliminary activity index. Ann Rheum Dis 2001; 60: 592-598.

7. Matucci-Cerinic M, Steen V D, Furst D, Seibold J. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Research & Therapy 2007; 9: S7.

8. Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of 6 min walk test. Ann Rheum Dis 2007; 66: 169-173.

9. Impens A, Schiopu E, Phillips K et al. Correlations of subjective ratings of dyspnea with traditional measures of parenchymal lung disease in systemic sclerosis with interstitial lung disease. Arthritis Rheum 2007; 26(Suppl 9): S486.

10. Garin MC, Highland KB, Silver and C Strange RM. Limitations to the 6-MWT in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheum 2009; 36: 330-336.